ERBB2 and colorectal carcinoma: Not only HER2 amplification but also HER2 activating mutations (S310F, L755S, V777L, V842I, and L866M) cause oncogenic transformations of colon epithelial cells and induce drug resistance to anti-EGFR therapies, cetuximab and panitumumab in CRC cell lines [25].